GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Established prognostic models for primary myelofibrosis (PMF) exist, including mutation-enhanced international prognostic scoring systems (MIPSS70 and MIPSS70-plus).
• There is a need for prognostic tools that are exclusively based on genetic markers for improved patient stratification in PMF.

Purpose of the Study:

• To evaluate the feasibility and accuracy of a genetically inspired prognostic scoring system (GIPSS) for primary myelofibrosis (PMF).
• To develop a novel prognostic model for PMF solely based on genetic risk factors.

Main Methods:

• Analysis of 641 cytogenetically annotated PMF patients with informative adverse mutations.
• Multivariable analysis to identify independent predictors of inferior survival.
• Development and internal validation of a four-tiered GIPSS model using hazard ratio-weighted risk points.

Main Results:

• Key predictors of inferior survival identified: "VHR" karyotype, "unfavorable" karyotype, absence of type 1/like CALR mutation, and presence of ASXL1, SRSF2, or U2AF1Q157 mutation.
• The GIPSS model stratified patients into low, intermediate-1, intermediate-2, and high-risk groups with distinct median survivals (26.4, 8.0, 4.2, and 2 years, respectively).
• The GIPSS model demonstrated predictive accuracy comparable to MIPSS70-plus upon internal validation.

Conclusions:

• The genetically inspired prognostic scoring system (GIPSS) is a feasible and accurate prognostic tool for primary myelofibrosis (PMF).
• GIPSS offers a low-complexity, genetics-based approach for predicting survival in PMF patients.
• This model represents a forward-looking prognostic strategy by relying exclusively on genetic risk factors.